The bull case for Eli Lilly and its long-stunted R&D operation rests largely on a potential string of FDA approvals for the much-hyped ramucirumab, and the Indiana drugmaker picked up its first, clearing the treatment to treat stomach cancer.

…read more

Source: FDA OKs Lilly’s blockbuster hopeful ramucirumab for stomach cancer


0 No comments